HER2-Specific Peptide (LTVSPWY) and Antibody (Herceptin) Targeted Core Cross-Linked Micelles for Breast Cancer: A Comparative Study
This study aims to prepare a novel breast cancer-targeted micelle-based nanocarrier, which is stable in circulation, allowing intracellular drug release, and to investigate its cytotoxicity, apoptosis, and cytostatic effects, in vitro. The shell part of the micelle is composed of zwitterionic sulfob...
Saved in:
Main Authors: | Nazende Nur Bayram (Author), Gizem Tuğçe Ulu (Author), Nusaibah Abdulsalam Abdulhadi (Author), Seda Gürdap (Author), İsmail Alper İşoğlu (Author), Yusuf Baran (Author), Sevil Dinçer İşoğlu (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2023-02-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Validation of ELISA Test-system for Trastuzumab (Herceptin, Hertikad) quantitative determination in biological fluids
by: V. V. Pisarev, et al.
Published: (2023) -
Based on whole-exome sequencing to explore the rule of Herceptin and TKI resistance in breast cancer patients
by: Liantao Guo, et al.
Published: (2024) -
TROIKA‐1: A double‐blind, randomized, parallel group, study aimed to demonstrate the equivalent pharmacokinetic profile of HD201, a potential biosimilar candidate to trastuzumab, versus EU‐Herceptin® and US‐Herceptin® in healthy male subjects
by: Martin Demarchi, et al.
Published: (2021) -
Cuidado Farmacêutico a pacientes em tratamento com Herceptin® (Transtuzumabe): um estudo de caso
by: Juliana dos Santos SILVA, et al.
Published: (2020) -
Prática de clínica dos enfermeiros portugueses: administração subcutânea de trastuzumab (herceptin®) e rituximab (mabthera®)
by: Alice Monteiro, et al.
Published: (2018)